$6.46 -0.18 (-2.71%)
11/20/2009 4:03 PM

Elan Corp, plc (ADR) (ELN)

CAPS Rating: 4 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Current Price $6.46 Mkt Cap $3.05B
Open $6.56 P/E Ratio 0.00
Prev. Close $6.64 Div. (Yield) N/A (N/A)
Daily Range $6.45 - $6.63 Volume 2,575,435
52-Wk Range $4.61 - $9.13 Avg. Daily Vol. 6,834,000

ELN News and Commentary

Caps

How do you think ELN will perform vs the S&P 500?

Add Stock to Watchlist

All Members

898 Outperform
66 Underperform
 

All-Star Members

199 Outperform
20 Underperform
 

Wall Street

3 Outperform
3 Underperform
 

Top ELN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

latimerburned (88.22)
Submitted August 15, 2009

They have taken away a lot of the financial risk with the JNJ deal so now its all about Tysabri and Alzheimers. I think that the benefits of Ty outweigh the risks as they are learning how to manage the drug so this one should do very well.

1 Comment | Reply | Report this Post

michjksn (< 20)
Submitted February 27, 2009

Historically poorly run company. One product which causes death all too often/terrible press. No products on horizon, including Bap, worth anything other than being money pits for underachievement. What R&D there was, has been all but killed off… More

0 Comments | Reply | Report this Post
ELN VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about ELN.

Recs

0
Member Avatar rainmaker59 (36.10) Submitted: 11/11/2009 9:29:44 PM : Outperform Start Price: $6.32 ELN Score: +2.73

Rulebreaker pick of Jan. 2009. All debt is related to massive R&D expenses. Leading edge of RX for Crohn's, MS and Alzheimer's.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar macginty (< 20) Submitted: 10/29/2009 1:43:34 PM : Outperform Start Price: $5.19 ELN Score: +21.66

The reason I feel that Eln will outperform is due to the underlying strength of a number of product lines in it's poertfolio e.g. the negative publicity regarding PML and Tysabri is exagerated and ignores the positive impact of the treatment on many lives.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar Oaklander (< 20) Submitted: 10/23/2009 3:28:21 PM : Outperform Start Price: $5.34 ELN Score: +19.54

Elan was hit hard today with some foul news out of Europe, but this shall pass. Tysabri has proven to have a high level of efficacy in the treatment of MS. In fact, it is the MOST effective treatment on the market today. Combined with some exciting Alzheimer's treatments coming down the line (Bapineuzumab, et al) and ongoing research into Parkinson's, Elan will certainly return handsomely given a few years.

Report this Post 0 Comments | Reply | Permalink
View All 208 Pitches »

Leaderboard

Find the members with the highest scoring picks in ELN.

Score Leader

BrianMotleyFool

BrianMotleyFool (89.77) Score: +120.20

The Score Leader is the member with the highest score across all their picks in ELN.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
PacificSexLegend 95.90 7/11/2008 Underperform 5Y $35.15 -81.62% -8.85% +72.78
mikealao < 20 2/14/2008 Underperform NS $25.20 -74.37% -16.46% +57.90
SAMMYSPOPS 37.31 4/30/2008 Underperform 3M $27.11 -76.17% -18.65% +57.52
sbtoloc 20.46 7/30/2008 Underperform 3Y $20.82 -68.97% -11.49% +57.49
eskymacka 87.38 3/3/2008 Underperform 1Y $22.88 -71.77% -14.34% +57.42
morningstarboy < 20 2/21/2008 Underperform NS $24.00 -73.08% -15.71% +57.37 1 Comment
sahzies 83.89 5/8/2008 Underperform 1Y $26.77 -75.87% -18.76% +57.11
ofriendly < 20 5/8/2008 Underperform 3M $26.17 -75.32% -18.82% +56.50
zim3888 < 20 5/19/2008 Underperform 1Y $27.04 -76.11% -20.54% +55.57 1 Comment
Walker7734 50.34 2/28/2008 Underperform NS $23.06 -71.99% -16.90% +55.09
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackUBS 88.39 7/20/2009 Outperform NS $7.65 -35.03% +11.10% -46.13 10/29/2009 @ $4.97
TrackRBCCapMkts 82.07 1/22/2009 Underperform NS $7.07 -8.63% +35.11% +43.73
TrackCanaccord 78.23 1/14/2009 Outperform NS $8.92 -27.58% +28.40% -55.98
TrackBreanMurray 87.51 7/11/2008 Underperform NS $34.91 -81.50% -8.58% +72.92
TrackPiperJaff 78.45 7/11/2008 Underperform NS $34.91 -81.72% -32.26% +49.47 4/3/2009 @ $6.38
TrackMerriman < 20 6/11/2008 Outperform NS $26.33 -75.47% -16.83% -58.63
TrackCarisandCo 76.69 5/15/2008 Underperform NS $27.10 -74.69% -38.11% +36.58 10/24/2008 @ $6.86
TrackCanaccord 78.23 3/26/2008 Underperform NS $20.78 -62.66% -35.50% +27.15 1/13/2009 @ $7.76
TrackCreditSuiss 90.95 3/5/2008 Outperform NS $21.93 -49.20% -5.94% -43.26 8/4/2008 @ $11.14
TrackLehmanBros 66.51 2/14/2008 Underperform NS $25.51 -54.68% -6.57% +48.11 8/6/2008 @ $11.56
TrackFBRCapitalM 73.72 10/2/2007 Underperform NS $21.19 +73.76% -18.96% -92.72 7/10/2008 @ $36.82
TrackEdwardOwens 98.46 9/30/2007 Outperform NS $21.04 -69.30% -24.86% -44.44 5 Comments
TrackJimCramer 36.31 8/28/2007 Underperform 3W $18.86 -65.75% -19.85% +45.90
TrackJimCramer 36.31 6/18/2007 Outperform 3W $21.68 -13.01% -6.00% -7.01 8/29/2007 @ $18.86
TrackUBS 88.39 8/14/2006 Underperform NS $14.52 +148.14% -2.27% -150.41 7/10/2008 @ $36.03
TrackJimCramer 36.31 3/2/2006 Underperform 3W $12.81 +69.24% +18.80% -50.44 6/19/2007 @ $21.68

Featured Broker Partners